Skip to main content
Simcere Pharmaceutical Group Limited logo

Simcere Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · S2P ISIN · HK0000658531 HKEX Manufacturing
Open in API
Filings indexed 577 across all filing types
Latest filing 2026-01-12 Transaction in Own Shar…
Country CN China
Listing HKEX S2P

About Simcere Pharmaceutical Group Limited

https://www.simcere.com/en/

Simcere Pharmaceutical Group Limited is an R&D-driven pharmaceutical company specializing in the discovery, development, and commercialization of innovative and branded generic prescription drugs. The company strategically focuses on core therapeutic areas, including neuroscience, anti-oncology, and inflammatory diseases. Simcere emphasizes synergistic innovation, evidenced by its development and launch of multiple Category I innovative pharmaceuticals and its strategic collaborations with global partners to advance novel treatments. These partnerships aim to address significant unmet medical needs and expand the company's portfolio across specialized disease areas.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is a 'Next Day Disclosure Return' (Form FF305) filed with the Stock Exchange of Hong Kong. It explicitly details the repurchase of 3,672,000 shares by Simcere Pharmaceutical Group Limited on 12 January 2026. According to the filing definitions, reports of a company buying back its own shares are classified as 'Transaction in Own Shares' (POS).
2026-01-12 English
PROPOSED SPIN-OFF AND SEPARATE LISTING OF SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. ON THE MAIN BOARD OF THE STOCK EXCHANGE OF HONG KONG LIMITED
M&A Activity Classification · 100% confidence The document is an official announcement from Simcere Pharmaceutical Group Limited regarding a 'Proposed Spin-off and Separate Listing' of its subsidiary, Simcere Zaiming. It details the rationale, listing rules implications (discloseable transaction), and the process for the spin-off. This falls under the category of M&A Activity (TAR), as it concerns corporate restructuring, spin-offs, and divestiture-related activities.
2026-01-09 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025
Regulatory Filings Classification · 95% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in securities, including share capital, treasury shares, and share options. Since it is a recurring regulatory filing regarding share capital and securities movements that does not fit into specific categories like 'Share Issue' (which usually refers to a specific event) or 'Transaction in Own Shares' (which is a specific buyback report), it is best classified as a general Regulatory Filing.
2026-01-06 English
VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR SIM0610 (EGFR/cMET BISPECIFIC ANTIBODY-DRUG CONJUGATE) ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement from Simcere Pharmaceutical Group Limited regarding the receipt of clinical trial approval for a new drug candidate (SIM0610) from the National Medical Products Administration. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general regulatory announcement regarding business development that does not fall into the other specialized categories, it is classified as a Regulatory Filing (RNS).
2025-12-23 English
VOLUNTARY ANNOUNCEMENT - ENTERING INTO EXCLUSIVE LICENSING AGREEMENT WITH IPSEN IN RELATION TO SIM0613 (LRRC15 ANTIBODY-DRUG CONJUGATE)
Capital/Financing Update Classification · 95% confidence The document is a voluntary announcement by Simcere Pharmaceutical Group Limited regarding entering into an exclusive licensing agreement with Ipsen for a drug candidate. It details the business development, terms of the licensing agreement, and background information about the drug and companies involved. There are no financial statements, regulatory certifications, or detailed financial results presented. The document is an announcement of a business development event related to licensing and collaboration, which fits best under Capital/Financing Update (CAP) as it involves potential milestone payments and royalties, indicating financing and capital implications. The document length is 4167 characters, which is relatively short but contains substantive information about the licensing deal rather than just a brief notice or report publication announcement. Therefore, the most appropriate classification is CAP with high confidence.
2025-12-22 English
VOLUNTARY ANNOUNCEMENT - THE INCLUSION OF ENZESHU AND ENDOSTAR IN THE NEW NATIONAL REIMBURSEMENT DRUG LIST
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement issued by Simcere Pharmaceutical Group Limited regarding the inclusion of two of its drugs, ENZESHU and ENDOSTAR, in the National Reimbursement Drug List (NRDL). It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general corporate announcement regarding business development and regulatory updates that does not fall into a more specific category, it is classified as a general regulatory filing.
2025-12-08 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.